Why the study?
Atherosclerotic cardiovascular disease begins early in life from cumulative lipoprotein exposure, supporting a paradigm of earlier identification and sustained lipid-lowering treatment, yet direct evidence in younger populations at low short-term risk remains limited.
Does early adoption of lipid-lowering strategies guided by lifetime lipid burden and subclinical atherosclerosis imaging reduce lifetime ASCVD events in individuals at increased ASCVD risk?
Does early adoption of lipid-lowering strategies guided by lifetime lipid burden and subclinical atherosclerosis imaging reduce lifetime ASCVD events in individuals at increased ASCVD risk?
This 2026 ACC Scientific Statement advocates for shifting toward earlier identification and sustained lipid-lowering treatment using lifetime risk, risk enhancers, and subclinical atherosclerosis imaging to reduce lifetime ASCVD events.
Answers are grounded in this paper and cite their sources.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“There is a strong rationale for both earlier and longer-term lipid lowering, including intensive lifestyle management and medications, in people with elevated ASCVD risk, especially related to earlier exposure to unfavorable lipid levels.”
Supports earlier lifetime lipid burden-guided therapy; extends cumulative LDL evidence to personalize ASCVD prevention.
Atherosclerotic cardiovascular disease (ASCVD) begins early in life, driven in large part by cumulative exposure to low-density lipoprotein cholesterol and other atherogenic lipoproteins. Contemporary evidence from epidemiologic cohorts, genetic studies, imaging studies, and lipid-lowering trials supports a paradigm of earlier identification and more sustained treatment of individuals at increased ASCVD risk. This American College of Cardiology Scientific Statement reviews the rationale for early adoption of lipid-lowering strategies, with emphasis on lifetime lipid burden, inherited and acquired risk enhancers, and the role of subclinical atherosclerosis assessment. Available clinical trial data suggest that greater absolute low-density lipoprotein cholesterol reduction and longer treatment duration can reduce ASCVD events, even though direct evidence remains limited in younger populations at low short-term risk. Atherosclerosis detected by imaging may identify individuals whose ASCVD risk is underestimated by traditional calculators, but optimal strategies for screening, treatment thresholds, safety, adherence, cost-effectiveness, and value require further study. Clinicians should integrate estimated short- and long-term risk, lipid burden, risk enhancers, imaging findings when appropriate, and patient preferences to guide individualized, shared decision making to reduce lifetime ASCVD risk.
No takes yet. Share an insight, caveat, or question.
Greenland et al. (2026) conducted a review in Atherosclerotic cardiovascular disease (ASCVD) and subclinical atherosclerosis. Early adoption of lipid-lowering strategies and subclinical atherosclerosis assessment was evaluated on Reduction of lifetime atherosclerotic cardiovascular disease (ASCVD) events. Early lipid-lowering strategies guided by lifetime lipid burden, risk enhancers, and subclinical atherosclerosis imaging are supported by contemporary evidence to reduce lifetime ASCVD risk.
Synapse has enriched 10 related papers. Consider them for comparative context: